A. N. Kovshik
A. N. Kovshik has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Galina V. Lukina
V.A. Nasonova Research Institute of Rheumatology
3 shared publications - E. V. Volnukhin
A.S. Loginov Moscow Clinical Scientific Center
2 shared publications - Elena N. Aleksandrova
A. S. Loginov Moscow Clinical Scientific Center
2 shared publications A. A. Novikov
Moscow Clinical Scientific and Practical Centre n. a. A. S. Loginov
1 shared publication- A. G. Klimets
Moscow Clinical Scientific and Practical Centre n. a. A. S. Loginov
1 shared publication - Alexander A. Novikov
A.S. Loginov Moscow Clinical Scientific Center
1 shared publication
Latest Publications
- 6 June 2025
- Published by Alfmed LLC in Medical alphabet
- No. 9,p. 11-16
Efficacy and safety of upadacitinib therapy in patients with rheumatoid arthritis in real-world clinical practice: 12-month follow-up results
Background/Purpose. Upadacitinib (UPA) is an oral Janus kinase inhibitor, which has selectivity of JAK1 over JAK2, JAK3, and tyrosine kinase 2. UPA demonstrated efficacy for the treatment of RA, with acceptable safety profiles. We analyzed efficacy and tolerability of UPA in small Russian cohort of patients with rheumatoid arthritis.Materials and methods. Patients (n=24) with high RA activity (DAS 28 5.1±1.1, SDAI 27,5±11,2, CDAI 24,5±9,7) and an inadequate response of synthetic DMARDs (mainly methotrexate, 71 %) and biologics (mainly TNF-α blockers, 24 %) were included in the study. The majority of patients were middle-aged (46,8±15,4), RF (88 %) and ACPA (84 %) positive, with moderate functional impairment – 1.6 (1.25–2). UPA were administered per os, 15 mg daily. The evaluation of the effectiveness of the therapy was carried out according to the EULAR/ACR 2011 criteria and using SDAI, CDAI.Results. UPA led to a significant (pConclusion. UPA has shown significant improvement clinical status in patients who had an inadequate response to previous therapy. UPA was well tolerated. AE were registered in a small number of patients.
- 6 June 2025
- Published by Alfmed LLC in Medical alphabet
- No. 9,p. 11-16
Efficacy and safety of upadacitinib therapy in patients with rheumatoid arthritis in real-world clinical practice: 12-month follow-up results
Background/Purpose. Upadacitinib (UPA) is an oral Janus kinase inhibitor, which has selectivity of JAK1 over JAK2, JAK3, and tyrosine kinase 2. UPA demonstrated efficacy for the treatment of RA, with acceptable safety profiles. We analyzed efficacy and tolerability of UPA in small Russian cohort of patients with rheumatoid arthritis.Materials and methods. Patients (n=24) with high RA activity (DAS 28 5.1±1.1, SDAI 27,5±11,2, CDAI 24,5±9,7) and an inadequate response of synthetic DMARDs (mainly methotrexate, 71 %) and biologics (mainly TNF-α blockers, 24 %) were included in the study. The majority of patients were middle-aged (46,8±15,4), RF (88 %) and ACPA (84 %) positive, with moderate functional impairment – 1.6 (1.25–2). UPA were administered per os, 15 mg daily. The evaluation of the effectiveness of the therapy was carried out according to the EULAR/ACR 2011 criteria and using SDAI, CDAI.Results. UPA led to a significant (pConclusion. UPA has shown significant improvement clinical status in patients who had an inadequate response to previous therapy. UPA was well tolerated. AE were registered in a small number of patients.
- 13 December 2021
- Published by Alfmed LLC in Medical alphabet
- No. 33,p. 16-19
Role of serum calprotectin in diagnosis of inflammatory bowel diseases in patients with ankylosing spondylitis (preliminary results)
Background. Patients with inflammatory bowel diseases (IBD) often have lesions of the musculoskeletal system, which is an extra-intestinal manifestation and mainly belongs to the group of seronegative spondyloarthritis (SPA). Ankylosing spondylitis (AS) is one of the main forms of diseases from the group of spondyloarthritis, associated with IBD. The frequency of AS in patients with IBD is of interest for elucidating the general pathophysiology of diseases. Colonoscopy is required to diagnose intestinal pathology. Colonoscopy in patients with AS to detect IBD, especially in the absence of intestinal symptoms, is very diffcult. Mainly for the diagnosis of IBD, the defnition of fecal calprotectin is used. Recently, there has been an interest in serum calprotectin, an increase in which is associated with a higher activity of the disease and is a marker of the intensity of inflammation in the intestine. However, there is currently no consensus on the clinical signifcance for serum calprotectin.The aim. To evaluate the role of serum calprotectin in diagnosis of inflammatory bowel disease in patients with ankylosing spondylitis.Materials and methods. In the analysis were included 50 patients with AS, fulflling the modifed New York criteria, among them were 36 (72%) men and 14 (28%) women, the mean age of patients was 42.5 ± 9.9, mean disease duration was 13.4 ± 8.7 years. All patients were examined with ESR, CRP, FC (range: 100–1800 µg/g), esophagogastroduodenoscopy, colonoscopy and quantitative analysis of the SC level using ELISA (Buhlmann MRP8/14 ELISA, range: 0.4–3.9 µg/ml).Results. All patients had a high disease activity, mean BASDAI was 5.3 ± 1.8, mean ASDAS CRP was 3.7 ± 1.01, mean ASDAS ESR was 3.6 ± 1.01. 78% patients had high FC level (more than 100 µg/g), while only 18% patients had an increase of SC level. IBD were diagnosed in 11 cases: 6 (12%) patients with CD and 5 (10%) patients with UC, in the remaining cases (78%) was no intestinal pathology. Only two patients with IBD had a high SC level. SC level was more correlated with ESR (r = 0.5) and CRP (r = 0.5) (p < 0.05) levels, than with FC level (r = 0.4) (p < 0.05).Conclusion. The results have shown that there was currently insuffcient data to assess the possibility of using SC in the diagnosis of IBD in patients with AS. There was a signifcant association between the SC, CRP and ESR, but not fecal calprotectin. Potentially SC may be more representative for systemic inflammation than intestinal inflammation.
- 13 December 2021
- Published by Alfmed LLC in Medical alphabet
- No. 33,p. 16-19
Role of serum calprotectin in diagnosis of inflammatory bowel diseases in patients with ankylosing spondylitis (preliminary results)
Background. Patients with inflammatory bowel diseases (IBD) often have lesions of the musculoskeletal system, which is an extra-intestinal manifestation and mainly belongs to the group of seronegative spondyloarthritis (SPA). Ankylosing spondylitis (AS) is one of the main forms of diseases from the group of spondyloarthritis, associated with IBD. The frequency of AS in patients with IBD is of interest for elucidating the general pathophysiology of diseases. Colonoscopy is required to diagnose intestinal pathology. Colonoscopy in patients with AS to detect IBD, especially in the absence of intestinal symptoms, is very diffcult. Mainly for the diagnosis of IBD, the defnition of fecal calprotectin is used. Recently, there has been an interest in serum calprotectin, an increase in which is associated with a higher activity of the disease and is a marker of the intensity of inflammation in the intestine. However, there is currently no consensus on the clinical signifcance for serum calprotectin.The aim. To evaluate the role of serum calprotectin in diagnosis of inflammatory bowel disease in patients with ankylosing spondylitis.Materials and methods. In the analysis were included 50 patients with AS, fulflling the modifed New York criteria, among them were 36 (72%) men and 14 (28%) women, the mean age of patients was 42.5 ± 9.9, mean disease duration was 13.4 ± 8.7 years. All patients were examined with ESR, CRP, FC (range: 100–1800 µg/g), esophagogastroduodenoscopy, colonoscopy and quantitative analysis of the SC level using ELISA (Buhlmann MRP8/14 ELISA, range: 0.4–3.9 µg/ml).Results. All patients had a high disease activity, mean BASDAI was 5.3 ± 1.8, mean ASDAS CRP was 3.7 ± 1.01, mean ASDAS ESR was 3.6 ± 1.01. 78% patients had high FC level (more than 100 µg/g), while only 18% patients had an increase of SC level. IBD were diagnosed in 11 cases: 6 (12%) patients with CD and 5 (10%) patients with UC, in the remaining cases (78%) was no intestinal pathology. Only two patients with IBD had a high SC level. SC level was more correlated with ESR (r = 0.5) and CRP (r = 0.5) (p < 0.05) levels, than with FC level (r = 0.4) (p < 0.05).Conclusion. The results have shown that there was currently insuffcient data to assess the possibility of using SC in the diagnosis of IBD in patients with AS. There was a signifcant association between the SC, CRP and ESR, but not fecal calprotectin. Potentially SC may be more representative for systemic inflammation than intestinal inflammation.
- 19 August 2021
- Published by Alfmed LLC in Medical alphabet
- No. 16,p. 26-29
Development of sulfasalazine-associated drug-induced lupus erythematosus in patient with rheumatoid arthritis (clinical case)
Drug-induced lupus syndrome (DLS) is a rare adverse event with a variety of drugs. More than a hundred of drugs are known that can cause the development of DLS, and this list is growing as new drugs appear. Physicians of any specialty can face such complications of therapy and should be aware of this pathology. The article presents an analysis of a clinical case of DLS development against the background of long-term administration of sulfasalazine in a patient with a reliable diagnosis of rheumatoid arthritis, as well as a literature review, which includes data on the prevalence, drug groups, clinical manifestations, diagnosis and treatment of this pathology.
- 19 August 2021
- Published by Alfmed LLC in Medical alphabet
- No. 16,p. 26-29
Development of sulfasalazine-associated drug-induced lupus erythematosus in patient with rheumatoid arthritis (clinical case)
Drug-induced lupus syndrome (DLS) is a rare adverse event with a variety of drugs. More than a hundred of drugs are known that can cause the development of DLS, and this list is growing as new drugs appear. Physicians of any specialty can face such complications of therapy and should be aware of this pathology. The article presents an analysis of a clinical case of DLS development against the background of long-term administration of sulfasalazine in a patient with a reliable diagnosis of rheumatoid arthritis, as well as a literature review, which includes data on the prevalence, drug groups, clinical manifestations, diagnosis and treatment of this pathology.